Phase Ia study of AVL 292 in volunteers
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2012
At a glance
- Drugs Spebrutinib (Primary)
- Indications Autoimmune disorders; B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Rheumatoid arthritis
- Focus Adverse reactions
- 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.
- 24 Jun 2011 Results presented at the Federation of Clinical Immunology Societies (FOCIS) in June 2011.
- 11 Jun 2011 Results presented at the 16th Congress of the European Haematology Association (EHA-2011).